The webinar is part one of a four part molecular tumor board series.

In this session, our expert panelists will review patient cases in which multiomic profiling has identified biomarkers that may or may not aid clinicians in making treatment decisions.

Precision oncology has seen a natural maturation from guiding therapy decisions based only on testing of specific, largely hotspot DNA mutations to testing that integrates assessment of sequence mutations, structural changes (i.e. deletions, amplifications, fusions), RNA, and protein levels. There are also genomic signatures, such as immune profiling gene expression signatures, tumor mutation burden (TMB), microsatellite instability (MSI), and homologous recombination deficiency (HRD) and human leukocyte antigen (HLA) status, that have further clinical implications in a pan-solid tumor setting.  

While these multiple layers of biomarker information have the potential to better inform individualized treatment plans and patient outcomes, they have also made it more difficult for oncologists to readily interpret test results and make clinical decisions. Our panel will discuss in detail several clinical cases where multiomic profiling was conducted and used to recommend a course of treatment for patients based on the available data.

The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.